Scientific Advisors

Company

Board

Management

Scientific Advisors

IP Rights

Pharma Holdings Contracted Scientific Advisors

Francois-Xavier Frapaise, CMO

FX Frapaise (Xavier) holds a MD from the University of Paris and brings on board over 40 years’ experience in the Pharma Industry (Sanofi, Abbott, Bayer, Merck, Gruenenthal as well as in several start-ups) in different roles such as VP R&D and Medical Affairs, CMO, CSO, and CEO. He has an extensive experience of international drug development (phase I to IV) and interaction with the FDA/EMA. One major focus of his experience is in the field of infectious diseases, such as Covid-19, RSV, hepatitis and C. difficile infections.

Xavier is located in Paris, France

Davey Smith, Scientific Advisor US

Dr. Smith obtained an MD from East Tennessee State university in 1996, is board certified in infectious diseases and is a professor of Medicine at University of San Diego.  He was elected to the American Society for Clinical Investigation in 2015 and works as Head of Division of Infectious diseases and public health at UC in San Diego. Since 2003 he has been awarded 37 mill USD in federal funding as PI. 

Dr. Smith was the protocol co-chair for the ACTIV-2 trial, which was part of the U.S. government’s response to COVID-19. He was also invited as speaker at Nobel Price symposium 2022 in Stockholm for the theme Covid-19 therapeutic interventions

Davey is located in San Diego, California, USA

Edvard Christian Fuglset Dahl

Martin Hoenigl, Scientific Advisor EU

Dr Hoenigl helds an MD from University of Graz and is holding an appointment as Associate Professor for Translational Mycology at the Division of Infectious Diseases, Medical University of Graz. Dr. Hoenigl has expertise in conducting research on clinical mycology, including fungal diagnostics and pharmacology of antifungal drugs and correlation with clinical findings, as well as virology with a focus on HIV and respiratory viruses. He is the current president of the European Confederation of Medical Mycology (ECMM), and the Vice Chair of the EHA Infections in Hematology SWG. He was awarded researcher of the year 2011 and is an author on 250 publications in the field of infectious diseases. 

Martin is located in Graz, Austria

Niklas Hammarstedt

Lars Heggelund, Scientific Advisor Nordic

Dr Heggelund holds a MD from university of Trondheim and became Specialist in Infectious Diseases in 2008. He is head of Research at Drammen Hospital, senior consultant at section of infectious disease and adjunct Professor at University of Bergen. His scientific focus is Microbiological and clinical immunological studies in infectious diseases, particularly airway infections and human immunodeficiency virus infection, which has led to 60 scientific publications. Dr Heggelund has been Chairman in Specialist Committee for Infectious Diseases, The Norwegian Medical Association

Lars is located in Drammen, Norway

Niklas Hammarstedt

Cecil Nick, Regulatory Strategic Advisor

Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and clinical development for over 40 years and has expertise inter alia in the development of anti-infective medicines including having supported many COVID-19 therapeutic interventions.  Mr Nick has applied his extensive scientific, drug development and regulatory experience in supporting clients with clinical development plans and regulatory strategies for EU, US and global approval. 

He is a Fellow of TOPRA and has been a guest lecture at UCL, Cardiff University and Greenwich University MSc Programs and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has authored many articles on regulatory and clinical development issues

Cecil is located in Surrey, UK